Tesofensine

Triple Monoamine Reuptake Inhibition (DAT, NET, SERT)#

Tesofensine is a phenyltropane-class SNDRI — a small molecule that blocks presynaptic reuptake of dopamine, norepinephrine, and serotonin by occupying the DAT, NET, and SERT transporters. Synaptic monoamine tone rises across all three systems, but the anti-obesity effect is driven primarily by the noradrenergic and dopaminergic components, with serotonin playing a modulatory role. This triple-transporter profile is what separates tesofensine from phentermine (predominantly NE-releasing) and from bupropion (NE/DA reuptake only) — the added dopaminergic weight is why the compound hits reward-driven eating, not just hunger, and why food noise quiets rather than just physical appetite.

"Co-treatment with metoprolol prevented the heart rate and blood pressure increases observed with tesofensine, without reducing its anorectic action." — Bentzen BH et al., Obesity (Silver Spring), 2013

The Bentzen finding is mechanistically telling: peripheral β1-blockade strips out the cardiovascular tail without touching appetite suppression, meaning the anorectic signal is a central monoaminergic effect, not a downstream consequence of sympathetic activation. This is what the Tesomet fixed-dose combination exploits.

Silencing of Lateral Hypothalamic GABAergic Neurons#

The most elegant piece of the mechanism came out in 2024. Tesofensine doesn't just broadly elevate monoamines — it targets a specific subset of GABAergic neurons in the lateral hypothalamus (LH) that tonically inhibit satiety circuits. Silencing these cells disinhibits downstream satiety and reward-integration pathways, producing the characteristic "I forgot to eat" phenomenology that users report.

"We found that tesofensine rapidly inhibited the firing of a subset of GABAergic neurons of the lateral hypothalamus (LH), which are known to regulate feeding behavior." — Perez CI et al., Front Pharmacol, 2024

This is a cleaner, more discrete central target than the diffuse stimulant-like action of amphetamine-class anorectics — and it lines up with clinical reports of smoother appetite control without the jagged, pyramiding-dose behavior seen with short-acting sympathomimetics.

Increased Resting Energy Expenditure and Fat Oxidation#

Beyond appetite, tesofensine modestly shifts the energy-balance equation on the expenditure side. Elevated noradrenergic tone drives lipolysis via β-adrenergic signaling in adipose tissue and raises resting metabolic rate, with the effect showing up most clearly during the nocturnal low-activity window.

"Tesofensine increased resting energy expenditure during the night by 6% as compared with placebo, and significantly reduced ratings of hunger and prospective food consumption." — Sjödin A et al., Int J Obes (Lond), 2010

A 6% nocturnal REE bump is not huge on its own, but stacked on top of the ~30% reduction in ad-libitum intake from the hypophagic effect, the two mechanisms compound — this is why Astrup's 24-week data showed placebo-subtracted losses of ~9% of body weight at 0.5 mg, substantially above what appetite suppression alone typically delivers.

Sympathomimetic Tone (the CV Signal)#

The same noradrenergic mechanism that drives appetite suppression and lipolysis also produces the dose-dependent rise in resting heart rate (~7–8 bpm at 500 mcg) and a smaller systolic BP bump. This is not an off-target effect — it is the mechanism showing itself peripherally. The practical consequence is that cardiovascular monitoring is non-negotiable, and stacking with other sympathomimetics (clen, ephedrine, yohimbine) from day one magnifies load unnecessarily. Peripheral β1-blockade (metoprolol 25–50 mg) cleanly separates the wanted central effect from the unwanted peripheral one, which is the entire rationale behind the Tesomet template.

Ultra-Long Half-Life Pharmacology#

Tesofensine's terminal half-life of ~220 hours (≈9 days), with an active metabolite (M1/NS2360) at ~400 hours, is unusual in this drug class and shapes how the compound behaves in practice.

"The estimated terminal half-life of tesofensine was approximately 220 h and of M1 was 400 h, indicating prolonged presence in plasma after cessation." — Lehr T et al., Br J Clin Pharmacol, 2007

Three downstream implications for protocol design:

1. Steady state takes 5–8 weeks. A dose titrated upward after three days is chasing a curve that hasn't expressed yet — the felt effect at week 1 on 250 mcg is nowhere near the steady-state effect at week 6 on the same dose.
2. No sharp rebound on cessation. Parent compound and M1 wash out over 2–3 weeks after the last dose, producing a built-in taper rather than the crash seen with short-half-life stimulants.
3. Drug-interaction windows are long. Starting an MAOI, a serotonergic agent, or another DAT inhibitor within 2–3 weeks of stopping tesofensine is effectively a co-administration. The washout respects the pharmacokinetics, not the calendar.

Common (most users)#

Most of what shows up in the first 2–4 weeks attenuates as steady state builds. These are the effects documented across the Astrup Phase II trial and the Sjödin energy-metabolism study, and they track with what forum users report at 250–500mcg.

• Dry mouth — by far the most frequent complaint (~35% at 0.5mg in trial data). Hydration and sugar-free gum handle it; no dose change needed.
• Insomnia and vivid dreams — driven by the noradrenergic and dopaminergic mechanism. Morning dosing is non-negotiable — dosing after noon with a ~220h half-life guarantees sleep disruption. Magnesium glycinate at night and tight sleep hygiene cover the rest.
• Early jitteriness / mild anxiety — most pronounced in week 1–2 of a new dose. Usually resolves by week 4 as monoamine tone equilibrates. If it doesn't, the dose is too high.
• Constipation — common on any appetite-suppressant cut where fiber intake drops alongside calories. Psyllium, adequate water, and keeping vegetables in the diet fix it.
• Reduced appetite overshoot — the anorectic effect is strong enough that protein intake drops without the user noticing. This is the single biggest pitfall for physique-focused users. Protein targets (≥1g/lb lean mass) are pre-planned and tracked, not left to hunger cues that no longer exist.

"Tesofensine increased resting energy expenditure during the night by 6% as compared with placebo, and significantly reduced ratings of hunger and prospective food consumption." — Sjödin et al., 2010

Uncommon (dose-dependent or individual)#

These scale with dose and show up more at 500–1000mcg than at 250mcg. They are the reason the Phase III lead dose settled at 0.5mg rather than 1mg.

• Resting heart rate elevation — roughly +7–8 bpm at 500mcg, +11 bpm at 1mg (Astrup et al., 2008). Baseline HR and weekly home-cuff readings are standard. Sustained resting HR >90 bpm is a dose-reduction trigger. The Tesomet template (metoprolol 25–50mg daily) flattens this cleanly:

"Co-treatment with metoprolol prevented the heart rate and blood pressure increases observed with tesofensine, without reducing its anorectic action." — Bentzen et al., 2013

• Blood pressure elevation — systolic +1–3 mmHg at 500mcg, larger at 1mg. Sustained readings >140/90 warrant either β1-blockade, a low-dose tadalafil add-on (2.5–5mg daily), or a step down to 250mcg.
• Irritability, emotional blunting, or low mood — plausible given triple monoamine reuptake inhibition. Users prone to depressive episodes or with a prior bad response to SNRIs should assume higher likelihood here. Discontinue if mood changes persist past week 4 at a stable dose.
• Palpitations / ectopy awareness — bloodwork and an ECG are appropriate if this surfaces, especially in users stacking with AAS or other sympathomimetics.
• Headache — usually in the first 1–2 weeks of titration; hydration-responsive.

Dose-escalation cadence: steady state takes 5–8 weeks because of the 9-day terminal half-life. Escalating after a few days overshoots real exposure. Each dose step is held for a minimum of 2 weeks — ideally 4 — before the next increase.

Rare but serious#

Low incidence but the warning signs warrant immediate discontinuation.

• Hypertensive episode (systolic >160 or diastolic >100 sustained) — stop the compound and seek evaluation. More likely in users with pre-existing untreated HTN or stacking with other sympathomimetics.
• Tachyarrhythmia / persistent palpitations with chest discomfort — stop, ECG, cardiology follow-up.
• Serotonin syndrome — essentially only seen with co-administration of other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, MDMA). Hyperthermia, agitation, clonus, diaphoresis — emergency presentation.
• Stimulant-induced psychosis / mania — rare, but the triple monoamine mechanism means individuals with a bipolar-spectrum or psychotic history are specifically at risk. Any emergent paranoia, grandiosity, or sleep-less euphoria is a stop signal.
• Severe depressive episode — the 1mg arm in Astrup's trial carried a mood AE signal. Any sustained low mood, anhedonia, or suicidal ideation warrants discontinuation — noting that washout itself is slow (2–3 weeks of residual drug after last dose).

Hard contraindications#

These are not judgment calls.

• Uncontrolled hypertension or tachyarrhythmia. The sympathomimetic signal is mechanistic, not an idiosyncratic side effect. Untreated HTN or HR-driven arrhythmia is disqualifying.
• Concurrent MAOIs. Absolute contraindication — hypertensive crisis and serotonin syndrome risk.
• Concurrent SSRIs, SNRIs, tramadol, or other serotonergic agents at therapeutic doses. Stacking triple monoamine reuptake inhibition onto existing serotonergic load is the textbook serotonin-syndrome setup.
• Concurrent cocaine, amphetamine, methylphenidate, or other DAT inhibitors. Additive dopamine transporter blockade with no ceiling safety data.
• Strong CYP3A4 inhibitors — ketoconazole, itraconazole, clarithromycin, ritonavir, high-volume grapefruit. Parent compound already has a 220-hour half-life; raising exposure further is not a managed risk.
• History of psychosis, bipolar disorder, or severe anxiety disorder. The monoamine profile is not appropriate here.
• Pregnancy or potential pregnancy. No reproductive safety data.
• Known pheochromocytoma or hyperthyroidism. Adding sympathomimetic tone to these is dangerous.

Gender and cycle considerations#

Efficacy and adverse-event profile track similarly across male and female subjects in the published trial data. Tesofensine is non-hormonal — no HPTA suppression, no virilization risk, no aromatization, no PCT requirement. It is compatible with on-cycle and post-cycle AAS protocols from an endocrine standpoint, though stacking it onto a trenbolone or high-androgen run that is already pushing cardiovascular load is a compounding decision users generally avoid. The 3-week residual drug tail after the last dose means any subsequent sympathomimetic (clen, ECA, yohimbine at full dose) is effectively stacking onto existing drug — the washout has to be respected, not assumed.